Brief: Oryzon Gets EMA Approval For Phase II Study Of Iadademstat In Thrombocythemia
24/02/2026 07:07
Feb 24 (Reuters) - Oryzon Genomics SA ORY.MC: RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE PHASE II STUDY OF IADADEMSTAT IN ESSENTIAL THROMBOCYTHEMIA SECONDARY OBJECTIVES INCLUDE DCHR RATE AND PHARMACOKINETIC PROFILE Source text Further company coverage: ORY.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28